Skip to content

Study · Randomized controlled trial · n = 28 · 1999

3 results

Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.

Van den Berghe G, Wouters P, Bowers CY, de Zegher F, Bouillon R, Veldhuis JD

European journal of endocrinology1 Jan 1999Cited by 26 (Europe PMC)

PMID10037246 (opens in a new tab)DOI10.1530/eje.0.1400017 (opens in a new tab)PepBankPUB-10037246
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In prolonged critically ill patients, GHRP‑2 infusion, but not GHRH or TRH, markedly synchronized GH, TSH and PRL serum profiles versus placebo.

    In plain wordsIn patients with long critical illness, GHRP‑2 made growth hormone, TSH and prolactin release move together, compared with placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseSynchrony of GH, TSH and PRL serum profiles
    Study

    n = 28

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kg/h · continuous infusion · 21 hoursAs given in this study (human).

    Source sentences

    Summary
    Infusion of GHRP-2, but not GHRH or TRH, markedly synchronized serum profiles of GH, TSH and PRL (all P< or =0.007).
    1 context sentence
    Summary · context
    obtained from prolonged critically ill patients by nocturnal blood sampling every 20 min for 9 h during 21-h infusions of either placebo (n=22), GHRH (1 microg/kg/h; n=10), GH-releasing peptide-2 (GHRP-2; 1 microg/kg/h; n=28), TRH (1 microg/kg/h; n=8) or combinations of these agonists (n=8).

Studies that did not test the peptide alone2

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 02HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In prolonged critically ill patients, adding GHRH to GHRP‑2 infusion kept only GH and PRL synchrony (P=0.003), more marked than with GHRP‑2 alone.

    In plain wordsIn patients with long critical illness, GHRH plus GHRP‑2 kept only growth hormone and prolactin in step, more than GHRP‑2 alone.

    Peptide
    GHRP-2
    Outcome
    MixedGH-PRL synchrony with GHRH plus GHRP-2
    Study

    n: not reported in source

    Comparator
    GHRP-2 alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    After addition of GHRH and TRH to the infusion of GHRP-2, only the synchrony between GH and PRL was maintained (P=0.003 for GHRH + GHRP-2 and P=0.006 for TRH + GHRH + GHRP-2), and was more marked than with GHRP-2 infusion alone (P=0.0006 by ANOVA).
    1 context sentence
    Summary · context
    obtained from prolonged critically ill patients by nocturnal blood sampling every 20 min for 9 h during 21-h infusions of either placebo (n=22), GHRH (1 microg/kg/h; n=10), GH-releasing peptide-2 (GHRP-2; 1 microg/kg/h; n=28), TRH (1 microg/kg/h; n=8) or combinations of these agonists (n=8).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism

    In prolonged critically ill patients, adding TRH and GHRH to GHRP‑2 infusion kept only GH and PRL synchrony (P=0.006), more marked than with GHRP‑2 alone.

    In plain wordsIn patients with long critical illness, TRH, GHRH and GHRP‑2 together kept only growth hormone and prolactin in step, more than GHRP‑2 alone.

    Peptide
    GHRP-2
    Outcome
    MixedGH-PRL synchrony with TRH plus GHRH plus GHRP-2
    Study

    n: not reported in source

    Comparator
    GHRP-2 alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    After addition of GHRH and TRH to the infusion of GHRP-2, only the synchrony between GH and PRL was maintained (P=0.003 for GHRH + GHRP-2 and P=0.006 for TRH + GHRH + GHRP-2), and was more marked than with GHRP-2 infusion alone (P=0.0006 by ANOVA).
    1 context sentence
    Summary · context
    obtained from prolonged critically ill patients by nocturnal blood sampling every 20 min for 9 h during 21-h infusions of either placebo (n=22), GHRH (1 microg/kg/h; n=10), GH-releasing peptide-2 (GHRP-2; 1 microg/kg/h; n=28), TRH (1 microg/kg/h; n=8) or combinations of these agonists (n=8).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.